Sign in
FENC Stock Price, Chart, Stats & News
Fennec Pharmaceuticals Inc.
Save
257.22M
Market cap
–
Current P/E
34.72x
Forward P/E
FENC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 91.55% |
Operating margin | -15.14% |
Pretax margin | -22.69% |
Net margin | -22.69% |
Effective tax rate | – |
ROA | -14.53% |
ROE | -236.42% |
D/E | – |
Interest coverage ratio | -3.16x |
FENC valuation
P/E | – |
P/S | 3.77x |
P/B | 5.26x |
P/CF | -14.77x |
P/FCF | -13.54x |
P/OCF | -14.77x |
PEG | 0.47x |
EV multiple | -32.24x |
About
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy.
Similar securities
Based on sector and market capitalization
Report issue